Previously submitted to: Interactive Journal of Medical Research (no longer under consideration since Jul 09, 2024)
Date Submitted: Mar 6, 2023
Open Peer Review Period: Mar 6, 2023 - May 1, 2023
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Bibliometric and visualization analysis of immunogenic cell death from 2012 to 2022
ABSTRACT
Background:
In recent years, immunogenic cell death (ICD) has been intensively studied. ICD is a form of regulated cell death (RCD) that is sufficient to trigger an adaptive immunological response specific for antigens produced on dying cells.
Objective:
This study aimed to analyze the foundation and frontiers of ICD research through bibliometric analysis.
Methods:
Articles and reviews on ICD from 2012 to 2022 were obtained from the Web of Science Core Collection and Pubmed. Countries, institutions, authors, journals, references, and keywords were analyzed and visualized using VOSviewer and CiteSpace.
Results:
In total, 2986 publications were included in the study. The global literature on ICD research has increased from 2012 to 2022. China and the United States contributed the greatest number of articles. Among the top 10 institutions, 50% were in France. The Chinese Academy of Sciences was the most productive institution. Kroemer G, Zitvogel L, Kepp O, and Galluzzi L were the most productive and co-cited authors. Oncoimmunology (n = 116), Frontiers in Immunology (n = 95), and Cancers (n = 92) published the most papers on ICD. The analysis of keywords found that current ICD-related research focuses on “PD-L1”, “cancer immunotherapy”, “tumor immune microenvironment”, and “nanoparticles”.
Conclusions:
ICD research has increased over the years, and future cooperation and interaction between countries and institutions must be expanded. Current ICD research focuses mostly on its mechanism molecules, the crosstalk between different forms of RCD, and its involvement in illnesses. The research on ICD in cancer and the new cancer therapy related to ICD may be future research hotspots.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.